SCHEMBL2822506

SCHEMBL2822506

CSc1ccc(Cn2cc(CO)cn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.40
▸ LMNA P02545 5/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ MAPK1 P28482 3/20 0.37
▸ TSHR P16473 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KLKB1 P03952 1/20 0.36
▸ NOTUM Q6P988 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2821950 0.82 HSD17B10 (0.43) HSD17B10LMNAMAPTHTTKDM4E
SCHEMBL3103391 0.80 NOTUM (0.54) HSD17B10LMNAMAPTHTTKDM4E
SCHEMBL29276697 0.79 LMNA (0.62) HSD17B10LMNAMAPTKDM4EKMT2A
SCHEMBL3085851 0.79 LMNA (0.61) HSD17B10LMNAMAPTHTTKDM4E
SCHEMBL1244019 0.78 L3MBTL1 (0.61) HSD17B10POLBL3MBTL1TSHR
SCHEMBL2052581 0.78 L3MBTL1 (0.52) MAPTKDM4EKMT2AMEN1POLB
SCHEMBL2818945 0.76 L3MBTL1 (0.63) HSD17B10L3MBTL1KCNH2KLKB1
SCHEMBL3085028 0.75 GAA (0.55) HSD17B10LMNAMAPTKMT2AMEN1
SCHEMBL18235821 0.75 KMT2A (0.66) HSD17B10LMNAMAPTHTTKDM4E
SCHEMBL29276679 0.74 MEN1 (0.55) LMNAMAPTHTTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA PPARA, PPARD, PPARG HSD17B10 140/4885LMNA 1512/4885MAPT 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback